The HOPE (Heart Outcomes Prevention Evaluation) study: The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin e in patients at high risk of cardiovascular events

Canadian Journal of Cardiology

Volumn 12, Issue 2, 1996, Pages 127-137

  Yusuf, Salim ^a  

^a HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

Angioterisin converting enzyme inhibitors; Cardiovascular prevention; HOPE Study; Randomized trial methodology; Vitamin E antioxidant

Indexed keywords

ALPHA TOCOPHEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

ADULT; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; EUROPE; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MEXICO; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SOUTH AMERICA; STROKE; UNITED STATES;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RAMIPRIL; RESEARCH DESIGN; RISK FACTORS; VITAMIN E;

EID: 0029917456     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Heart and Stroke Foundation of Canada. Cardiovascular disease in Canada, 1993. Ottawa: Heart and Stroke Foundation of Canada, 1994.
2. Martin MJ, Hulley SB, Brown WS, et al. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361,662 men. Lancet 1986;ii:933-6.
3. Steinberg D, Parthasarathy S, Carew TE, Khoo J, Witztum J. Beyond cholesterol. Modifications of low-density lipoprotein that increase its arherogenicity. N Engl J Med 1989;320:915-24.
4. Berry EM. The effects of nutrients on lipoprotein susceptibility to oxidization. Curr Opin Lipidol 1992;3:5-11.
5. Dzau VJ. Cardiac renin-angiotensin system. Molecular and functional aspects. Am J Med 1988;84(Suppl 3A):22-7.
6. Dzau VJ. Angiotensin converting enzyme inhibitors and the cardiovascular System. J Hypertens 1992;10(Suppl 3):S3-10.
7. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
8. SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
9. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
10. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
11. Naftilan AJ, Pratt RE, Eldridge CS, et al. Angiotensin II induces c-fos expression in smooth muscle via transcriptional control. Hypertension 1989;13:706-11.
12. Alderman MH, Madhavan SH, Ooi WL, et al. Association of the rerun-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-104.
13. Dunn FG, Orsmon W, Venture HO. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984;53:105-8.
14. Lonn E, Yusuf S, Jha P, et al. Emerging role of angiotensin converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
15. Cambien F, Poirier O, Leclerc L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-4.
16. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. AmJ Clin Nutr 1991;53(Suppl 1): S326-34.
17. Stampfer MJ, Hennekens CH, Manson JA, et al. A prospective study of vitamin E consumption and risk for coronary disease in women. N Engl J Med 1993;328:1444-9.
18. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and risk of coronary heart disease among men. N Engl J Med 1993;328:1450-6.
19. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
20. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins (E, C and carotenes) and cardiovascular disease: A critical summary of epidemiological and clinical trial data. Ann Intern Med 1995;123:860-72.
21. Ostfled AM. A review of stroke epidemiology. Epidemiol Rev 1980;2:136-52.
22. Canada Heart Health Surveys Research Group. Canada Heart Health Surveys: a profile of cardiovascular risk. Can Med Assoc J 1992;146 (Special Suppl):1-56.
23. Statistics Canada. Population Projections for Canada, Provinces and Territories. Ottawa: Statistics Canada, 1990.
24. Peto R. Clinical trial methodology. Biomedicine 1978;2 (Special Issue):24-36.
25. Yusuf S, Peto R, Collins R. Why do we need some large, simple, randomized trials? Stat Med 1984;3:409-20.
26. ISIS Collaborative Group. A randomised trial of intravenous atenolol among 16,027 patients with suspected acute myocardial infarction: ISIS-1. Lancet 1986;ii:57-66.
27. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither, among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;ii:349-60.
28. Knekt P, Aromaa A, Maatela J, et al. Vitamin E and cancer prevention. Am J Clin Nutr 1991;53(Suppl 1):S283-6.
29. Burton GW, Traber MG. Vitamin E antioxidant activity, biokinetics and bioavailability. Annu Rev Nutr 1990;10:357-82.
30. Bendich A, Machlin LJ. Safety of oral intake of vitamin E. Am J Clin Nutr 1988;48:612-9.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
32. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient: II analysis and examples. Br J Cancer 1977;35:1-39.
33. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-200.
34. 2Indomised trials of antiplatelet therapy-I. Prevention of death, myocardial inferction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
35. Yusuf S, Zucker D, Peduzzi R, et al. Effect of coronary artery bypass graft surgery on survival: overview of ten-year results from randomized trials. Lancet 1994;344:563-70.
36. Goldman S, Copeland JG, Moritz T, et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and the effects of antiplatelet therapy: results of a Veterans Administration cooperative study. Circulation 1989;80:1190-7.
37. Holmes DR, Derre KM, William D, et al. Long term outcome of patients with depressed left ventricular function undergoing percutaneous transluminal coronary angioplasty: the NHLBI Registry. Circulation 1993;87:21-9.
38. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment of diabetic retinopathy study report 14. JAMA 1992;266:1292-300.
39. Stamler J, Vaccoro O, Neaton JD. Diabetes, other risk factors and 12-year cardiovascular mortality for men screening in the Multiple Risk Factor intervention Trial. Diabetes Care 1992;16:434-44.
40. Uusilupa MIJ, Niskanen KK, Sictonon O, et al. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level and abnormalities in lipoprotein composition in non-insulin dependent diabetic and non-diabetic subjects. Circulation 1990;82:27-36.
41. National Diabetes Data Group. Diabetes in America: Diabetes Data Complied 1984 [NIH publication 85-1460]. Washington: US Dept of Health and Human Services, 1985.